Pfizer
PFE

Pfizer (PFE) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
GuggenheimMaintainedBuy$31.00 from $35.00Aug 7, 2026
GuggenheimMaintainedBuy$35.00 from $36.00Jul 13, 2026
BMO CapitalMaintainedOutperform$30.00 from $34.00Jul 13, 2026
B of A SecuritiesMaintainedNeutral$26.00 from $27.00Jul 10, 2026
JP MorganMaintainedNeutral$28.00 from $30.00Jul 8, 2026
HSBCDowngradedBuy → Hold$28.00 from $32.00Jul 6, 2026
Cantor FitzgeraldMaintainedNeutral$27.00Jul 6, 2026
RBC CapitalUpgradedUnderperform → Sector Perform$25.00Jun 10, 2026
CitigroupMaintainedNeutral$27.00 from $26.00Apr 29, 2026
RBC CapitalMaintainedUnderperform$25.00Apr 20, 2026
CICCInitiated CoverageOutperform$33.00Apr 16, 2026
UBSMaintainedNeutral$27.00 from $25.00Apr 13, 2026
Morgan StanleyMaintainedEqual-Weight$28.00 from $27.00Apr 10, 2026
B of A SecuritiesMaintainedNeutral$26.00 from $27.00Apr 9, 2026
GuggenheimMaintainedBuy$36.00 from $35.00Mar 24, 2026
HSBCMaintainedBuy$32.00 from $29.00Mar 17, 2026
Argus ResearchUpgradedHold → Buy$35.00Mar 2, 2026
RBC CapitalInitiated CoverageUnderperform$25.00Feb 25, 2026
BarclaysInitiated CoverageUnderweight$25.00Feb 20, 2026
Cantor FitzgeraldMaintainedNeutral$27.00Feb 4, 2026

Frequently asked questions

  • What is the latest analyst rating on PFE?

    On Aug 7, 2026, Guggenheim maintained Pfizer at Buy with a price target of $31.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.